3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Colorectal Neoplasms
11
Neoplasm Metastasis
10
Lung Neoplasms
7
Neoplasms
6
Colonic Neoplasms
6
Pancreatic Neoplasms
4
Carcinoma, Renal Cell
2
Advanced Solid Tumor
2
Solid Tumors
1
Resectable Non-Small Cell Lung Cancer
1
Rectal Neoplasms
1
Kidney Neoplasms
1
Healthy Adults
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Fluorouracil
267
Oxaliplatin
266
Capecitabine
224
Leucovorin
209
Irinotecan
151
Radiotherapy
131
Bevacizumab
112
Cetuximab
81
Folfox protocol
48
Surgical Procedures, Operative
44
Radiation
41
Drug Therapy
41
Neoadjuvant Therapy
40
Chemoradiotherapy
33
Chemotherapy, Adjuvant
32
Panitumumab
27
XELOX
25
Magnetic Resonance Spectroscopy
22
Radiotherapy, Intensity-Modulated
21
Floxuridine
17
Biopsy
16
Nivolumab
15
Gemcitabine
15
Early Intervention, Educational
15
pembrolizumab
14
Laparoscopy
14
IFL protocol
14
Celecoxib
14
trifluridine tipiracil drug combination
13
Gene Expression Profiling
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Rectal Neoplasms
×
adagrasib
×
Clear all
NCT04793958
2026-04-27
KRYSTAL-10
Mirati Therapeutics Inc.
Phase 3
Active not recruiting
461 enrolled